Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03383055 | CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig | completed | Phase 1 | 28 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT00421525 | Phase I/II Study of hLL1 in Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT00546793 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL |
| completed |
| Phase 1 / Phase 2 |
| 32 |
| Gilead SciencesINDUSTRY |
| 1 |
| Aug 16, 2021 |
| clinicaltrials |
| NCT01953692 | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | completed | Phase 1 | 197 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 4, 2021 | clinicaltrials |
| NCT00406809 | A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 81 | AbbVie (prior sponsor, Abbott)INDUSTRY | 2 | Aug 2, 2021 | clinicaltrials |
| NCT01794507 | A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy | completed | Phase 1 | 66 | AbbVieINDUSTRY | 3 | Aug 2, 2021 | clinicaltrials |
| NCT02265731 | Study Evaluating Venetoclax in Subjects With Hematological Malignancies | completed | Phase 1 / Phase 2 | 38 | AbbVieINDUSTRY | 1 | Aug 2, 2021 | clinicaltrials |
| NCT03665155 | First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody | completed | Phase 1 / Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT02650999 | Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas | completed | Phase 1 / Phase 2 | 12 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT02283775 | SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients(PomdeSAR) | completed | Phase 1 | 54 | SanofiINDUSTRY | 1 | Jul 9, 2021 | clinicaltrials |
| NCT02933320 | BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia | completed | Phase 1 / Phase 2 | 14 | Cancer Research UKOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT00794638 | A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 9 | SymBio PharmaceuticalsINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT01822509 | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | completed | Phase 1 | 71 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2021 | clinicaltrials |
| NCT02569320 | HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 | 9 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT03259529 | Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL(BeGeRN) | completed | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT02609230 | A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma | completed | Phase 1 | 33 | Fox Chase Cancer CenterOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT02669017 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | completed | Phase 1 | 183 | ADC Therapeutics S.A.INDUSTRY | 3 | May 19, 2021 | clinicaltrials |
| NCT02129582 | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT02841033 | Daratumumab for the Treatment of Patients With AL Amyloidosis | completed | Phase 1 / Phase 2 | 22 | Boston Medical CenterOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT01742988 | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | completed | Phase 1 | 106 | Curis, Inc.INDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT00981708 | Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL) | completed | Phase 1 / Phase 2 | 37 | University of AthensOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT02545907 | A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis(CATALYST) | completed | Phase 1 / Phase 2 | 10 | University College, LondonOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT00858234 | Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098) | completed | Phase 1 | 9 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 9, 2021 | clinicaltrials |
| NCT02431208 | A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) | completed | Phase 1 | 85 | Hoffmann-La RocheINDUSTRY | 1 | Apr 2, 2021 | clinicaltrials |
| NCT03381768 | Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma | completed | Phase 1 | 8 | Lars Møller PedersenOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT02948283 | Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia | completed | Phase 1 | 3 | City of Hope Medical CenterOTHER | 1 | Feb 12, 2021 | clinicaltrials |
| NCT01713582 | A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) | completed | Phase 1 | 141 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT02095834 | Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT00621244 | A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies | completed | Phase 1 / Phase 2 | 175 | Novartis PharmaceuticalsINDUSTRY | 3 | Jan 5, 2021 | clinicaltrials |
| NCT01474681 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 27 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 30, 2020 | clinicaltrials |
| NCT00424983 | Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT00532389 | Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma | completed | Phase 1 | 62 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 19, 2020 | clinicaltrials |
| NCT00532675 | Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma. | completed | Phase 1 | 46 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT00708292 | A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. | completed | Phase 1 / Phase 2 | 29 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 17, 2020 | clinicaltrials |
| NCT01456689 | A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 79 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT02144038 | Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 | 20 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 17, 2020 | clinicaltrials |
| NCT02160951 | Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies | completed | Phase 1 | 13 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 17, 2020 | clinicaltrials |
| NCT01275209 | Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma(LIFT) | completed | Phase 1 | 1 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 8, 2020 | clinicaltrials |
| NCT02831686 | A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma | completed | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT02504359 | Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | completed | Phase 1 | 11 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT02580552 | Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL | completed | Phase 1 | 66 | miRagen Therapeutics, Inc.INDUSTRY | 1 | Nov 23, 2020 | clinicaltrials |
| NCT00642954 | Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074) | completed | Phase 1 | 31 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 18, 2020 | clinicaltrials |
| NCT01155583 | Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 45 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 16, 2020 | clinicaltrials |
| NCT02852837 | Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy | completed | Phase 1 | 50 | Janssen Research & Development, LLCINDUSTRY | 1 | Nov 16, 2020 | clinicaltrials |
| NCT03688152 | A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma | completed | Phase 1 | 9 | Incyte CorporationINDUSTRY | 1 | Nov 10, 2020 | clinicaltrials |
| NCT01943682 | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | completed | Phase 1 | 27 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 9, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 17, 2021source: clinicaltrials